Slaughter and May, Hong Kong, advised Goldman Sachs (Asia) L.L.C. (“Goldman Sachs”) as placing agent on a placing of 118,000,000 ordinary shares of CStone Pharmaceuticals (“CStone”). The placing (the “Placing”) completed on 22 April 2026, raising HK$1.05bn (approximately US$134mn) for CStone and representing approximately 7.4% of CStone’s total issued shares after the Placing. CStone intends to use the net proceeds from the Placing to fund the ongoing and growing research and development efforts relating to CStone’s “Pipeline 2.0” assets, including in particular CS2009, CS5001 and other pre-clinical assets, as well as for general corporate purposes.
CStone is an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, dedicated to addressing patients’ unmet medical needs in China and globally. CStone has been listed on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX: 2616) since February 26, 2019.
Goldman Sachs is a licensed corporation under the Securities and Futures Ordinance and is licensed to carry out Type 1 (dealing in securities), Type 4 (advising on securities), Type 5 (advising on futures contracts), Type 6 (advising on corporate finance) and Type 9 (asset management) regulated activities.